Detalhes do Documento

  Introduction: Growing demand for fast, sensitive and simple diagnostic tools are driving the innovation of nanobiosensors, for point-of-care application. By combining state-of-the-art biosensing technologies and micro-scale platforms, they facilitate rapid in situ analyses of disease biomarkers for infectious diseases, cancer, and a wide range of diseases. There are several new modified nanomaterial-based biosensors (including modified graphene, carbon nanotubes, quantum dots and noble metals nanoparticles) that could offer desired sensitivity and specificity, combined with microfluidic and wireless systems. Objectives: The present paper aims to review the technical aspects of the new generation of biosensors and its potential uses in point-of-care evidence-based diagnostics. Methodology: A literature search was conducted across PubMed, ScienceDirect, and MDPI, focusing on peer-reviewed articles from 2010 to 2024, with priority given to studies from 2019–2024. A total of 63 articles were identified; 47 were included in this review, and 16 were excluded based on relevance. Results: We provide examples of the clinical relevance of these tools from pathogen detection as well as oncology. The use of nanobiosensing for decentralized/point-of-care/personalized health care has great potential even in the context of remaining challenges including standardization practices and biofouling related problems, especially when multidisciplinary innovations are united. Conclusion: In conclusion, while challenges continue to remain such as standardization and biofouling, the future of nanobiosensors as a key component in decentralized and personalized healthcare remains bright when supported by innovations stemming from interdisciplinary collaboration.